3 results
Approved WMOCompleted
Primary: progression-free survival in the GSK1120212-group in comparison with the docetaxel group. Secondary: safety and tolerability, response rate, duration of response, overall survival, PK.
Approved WMOCompleted
The objective of this study is to assess the efficacy and safety of 52 weeks once daily treatment with orally inhaled tiotropium plus olodaterol fixed dose combination compared with the individual components tiotropium and olodaterol (delivered by…
Approved WMOPending
The primary endpoint (equal or improved MSQoL-54 and Eq5d) at which the value of telemonitoring is determined is t = 2 years.Mapping the effects of digital consultations or hospital visits, for MS patients, informal carers and the Isala…